Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth is a heavy metal compound used in the treatment of *Helicobacter pylori* infection, often as part of a quadruple therapy regimen. In the context of research at National Taiwan University Hospital, it is being studied for its direct antimicrobial effects and how intragastric pH influences its efficacy. Bismuth acts by lysing *H. pylori* cells, inhibiting bacterial enzymes such as urease and alcohol dehydrogenase, and preventing adherence to the gastric mucosa. It does not typically develop bacterial resistance, making it a crucial component in overcoming antibiotic-resistant strains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth.